Computerized Intervention for Loneliness

January 26, 2021 updated by: Jesse Cougle, Florida State University
This study assesses whether a month long computerized interpretation bias modification intervention will reduce levels of loneliness compared to a control treatment.

Study Overview

Detailed Description

This study hopes to assess whether a month long interpretation bias modification intervention will reduce levels of loneliness compared to a control treatment. Participants will be randomized into an active treatment condition or a control treatment that involves a healthy living and relaxation protocol. The investigators hypothesize that participants in the IBM condition will have lower levels of negative interpretation bias and loneliness than those in the healthy habits condition at post treatment and follow up. The investigators further hypothesize that the effects of IBM on loneliness will be accounted for by changes in interpretation bias.

Study Type

Interventional

Enrollment (Actual)

67

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Tallahassee, Florida, United States, 32306
        • Florida State University, Department of Psychology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Score of >48 on the UCLA Loneliness Scale

Exclusion Criteria:

  • Concurrent psychotherapy for social anxiety or depression
  • Unstable psychotropic medication status (i.e. a change within the last month)
  • History of psychotic or (hypo)manic symptoms
  • Alcohol or other substance abuse or dependence within the last three months
  • Previous participation in a similar IBM study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Active Treatment
Interpretation Bias Modification for Loneliness
Participants will receive eight treatment sessions. They will be presented with ambiguous training scenarios on a computer screen. Scenarios will be presented in two discrete formats: a word-sentence relatedness task (adapted from Beard & Amir, 2008 and Beard, Weisberg, & Amir, 2011), and a sentence completion and comprehension task (adapted from paradigms used by Mathews and Mackintosh (2000), Steinman and Teachman (2010), and Beard and Amir (2008)). Both of these formats have been used to reduce maladaptive threat interpretations and increase benign interpretations.
ACTIVE_COMPARATOR: Control Treatment
Healthy Habits Psychoeducation and Relaxation.
Participants will receive eight computerized sessions consisting of psychoeducation on healthy behaviors as well as relaxing video clips with pleasant music (e.g., videos of rainforests, wildlife, and space). These sessions will be matched for time with the active condition, lasting approximately 25-30 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep. The relaxing videos will be presented after the psycho-education in each session. At the conclusion of the study, participants will be provided with the active IBM treatment free of charge if they wish to receive it.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
UCLA Loneliness Scale (ULS)
Time Frame: Change in loneliness from baseline to post treatment (4weeks) and three month follow up (16 weeks)
A 20 item Self report scale measuring loneliness. Scales range from 0 to 60 with higher scores indicating a higher level of loneliness.
Change in loneliness from baseline to post treatment (4weeks) and three month follow up (16 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Multidimensional Scale of Perceived Social Support
Time Frame: Change in Perceived Social Support from baseline to post treatment (4weeks) and three month follow up (16 weeks)
Self-report scale that measures perceived levels of social support. Scores range from 12 to 84 with higher scores indicating higher levels of perceived social support. The three subscales (friends, family and significant other) all have a range of 4 to 28 with higher scores indicating higher levels of perceived social support.
Change in Perceived Social Support from baseline to post treatment (4weeks) and three month follow up (16 weeks)
Social Phobia inventory
Time Frame: Change in social anxiety symptoms from baseline to post treatment (4 weeks) and three month follow up (16 weeks)
Self-report scale that measures Social anxiety symptoms. Scores range from 0 to 68 with higher scores indicating higher levels of social anxiety symptoms.
Change in social anxiety symptoms from baseline to post treatment (4 weeks) and three month follow up (16 weeks)
State-Trait Inventory for Cognitive and Somatic Anxiety-Trait Version (STICSA-T)
Time Frame: Change in overall anxiety symptoms from baseline to post treatment (4 weeks) and three month follow up (16 weeks)
Self-report measure used to assess overall anxiety symptoms. Scores range from 21 to 84 with higher scores indicating higher levels of overall anxiety.
Change in overall anxiety symptoms from baseline to post treatment (4 weeks) and three month follow up (16 weeks)
Center for Epidemiological Studies Depression Scale (CES-D)
Time Frame: Change in depression symptoms from baseline to post treatment (4 weeks) and three month follow up (16 weeks)
Self-report measure used to assess depressive symptoms. Total scores range from 0 to 60 with higher scores indicating a higher level of depressive symptoms.
Change in depression symptoms from baseline to post treatment (4 weeks) and three month follow up (16 weeks)
Interpersonal Needs Questionnaire (INQ)
Time Frame: Change in suicide vulnerability from baseline to post treatment (4 weeks) and three month follow up (16 weeks)
Self report measure of suicide vulnerability. Total scores range from 15 to 105, with higher scores indicating a higher vulnerability for suicide.
Change in suicide vulnerability from baseline to post treatment (4 weeks) and three month follow up (16 weeks)
Interpretations Questionnaire- Social Subscale (IQ-S)
Time Frame: Change in interpretation style from baseline to post treatment (4 weeks) and three month follow up (16 weeks)
Self report measure of interpretation bias of ambiguous social situations. Scales range from 0-44 with higher scores indicating a higher level of negative interpretation bias in social situations.
Change in interpretation style from baseline to post treatment (4 weeks) and three month follow up (16 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 25, 2019

Primary Completion (ACTUAL)

April 30, 2020

Study Completion (ACTUAL)

April 30, 2020

Study Registration Dates

First Submitted

February 11, 2019

First Submitted That Met QC Criteria

February 11, 2019

First Posted (ACTUAL)

February 15, 2019

Study Record Updates

Last Update Posted (ACTUAL)

January 29, 2021

Last Update Submitted That Met QC Criteria

January 26, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • 2018.25994

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Loneliness

Clinical Trials on Interpretation Bias Modification for Loneliness

3
Subscribe